Wednesday, March 30, 2022 12:00:03 PM
Have to remember, they said something about releasing information on the Ph 3 in the 3rd qtr. So as the 3rd qtr approaches, be my guess that we might finally see some 'interest' from the short termers, speculators who watch bios for these type of events to show up and promote a little demand (given this one isn't a household name, the product isn't going to have a 'well known' market to enter into, not sure how many are even paying attention to this one)..
So own some shares, intend to do some adding for the PH 3 release and hopefully its as good as the PH 2 and they proceed with an NDA..
Recent ATNM News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/08/2024 11:51:04 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/06/2024 12:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:12:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 10:05:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/05/2024 10:00:36 PM
- Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors • PR Newswire (US) • 11/04/2024 12:30:00 PM
- Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology • PR Newswire (US) • 09/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 09:15:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:34 AM
- Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. • PR Newswire (US) • 08/05/2024 11:00:00 AM
- Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications • PR Newswire (US) • 08/01/2024 12:00:00 PM
- Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University • PR Newswire (US) • 07/25/2024 12:45:00 PM
- Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US • PR Newswire (US) • 07/25/2024 11:30:00 AM
- Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial • PR Newswire (US) • 06/14/2024 12:30:00 PM
- Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/11/2024 12:30:00 PM
- Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity • PR Newswire (US) • 05/15/2024 12:30:00 PM
- Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas • PR Newswire (US) • 05/14/2024 10:38:00 PM
- Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 05/13/2024 12:30:00 PM
- Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy • PR Newswire (US) • 03/26/2024 11:18:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM